FBRX Stock Analysis: Buy, Sell, or Hold?
FBRX - Forte Biosciences, Inc. Common Stock
$25.58
0.72 (2.90%)
▲
5d:
-5.29%
30d:
-19.46%
90d:
-6.2%
HOLD
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Mar 27, 2026
0d
Smart Money Accumulation
FBRX is down 8.0% this week, but smart money is accumulating calls. Top strike: $40 2026-05-15 with 10 OI. Call ratio: 100% View Scanner →
Strength: 9.0/10
Get Alerted When FBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FBRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: FBRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: FBRX is currently trading at $25.58, which is considered slightly low relative to its 30-day fair value range of $25.35 to $29.42.
Technical Outlook: Technically, FBRX is in a uptrend. Immediate support is located at $22.01, while resistance sits at $29.62.
Market Sentiment: FBRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $63.75 (+149.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FBRX is in a uptrend. Immediate support is located at $22.01, while resistance sits at $29.62.
Market Sentiment: FBRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $63.75 (+149.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$25.35 -
$29.42
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.2% below Wall St target ($63.75)
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$25.35 -
$29.42
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$5.26
(20.5%)
Support & Resistance Levels
Support Level
$22.01
Resistance Level
$29.62
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.07
Wall Street Target
$63.75
(+149.2%)
Share & Embed Analysis
Last updated: April 02, 2026 8:49 PM ET
Data refreshes hourly during market hours. Next update: 9:49 PM
Data refreshes hourly during market hours. Next update: 9:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$138 | 61 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
